Having trouble viewing this email? View in your browser.

9 January 2018

Dear colleagues,

The ECCMID 2018 Programme Committee is currently planning the scientific programme for our congress, which will take place from 21 – 24 April 2018 in Madrid, Spain. We will then inform abstract submitters about acceptance of their research.

Last month, the Pew Trust published an analysis covering non-traditional products to tackle bacterial infections. It lists about 32 products including vaccines, microbiome products, immune enhancers, and more.

Your ESCMID communications editors


Main ECCMID 2018 sessions start Saturday morning on 21 April!

We would like to point out that the main scientific programme of ECCMID 2018 will start on Saturday morning (21 April) already. The ECCMID 2018 Programme Committee has adjusted the order of the sessions to give attendees more options to participate in educational sessions.

This year the two-hour educational workshops will take place throughout the four congress days. The programme on Saturday includes symposia dedicated to regional issues affecting Africa & the Middle East and India & the Far East as well as symposia covering hot topics including multidrug-resistant fungi, antibiotics in chronic infections or the emergence of arboviruses.

› Read more

CMI highlight: management of KPC-producing Klebsiella pneumoniae

ESCMID’s Critically Ill Patients Study Group in cooperation with researchers from Hellenic Society of Chemotherapy and SocietÓ Italiana di Terapia Antinfettiva aimed to provide practical suggestions for physicians dealing with the management of infections with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) in critically ill patients. The researchers from Italy and Greece addressed several key aspects including the prevention of colonization in a patient, the prevention of colonization of his or her contacts and the reduction of mortality in the infected patient by rapidly diagnosing the causative agent and promptly adopting the best therapeutic strategy. The researchers concluded that diagnostic technologies can speed up the diagnosis of KPC-KP infections. Combination treatment should be preferred to monotherapy in cases of severe infections. For non–critically ill patients without severe infections, results from randomized clinical trials are needed for ultimately weighing benefits and costs of using combinations rather than monotherapy. Multifaceted infection control interventions are needed to decrease the rates of colonization and cross-transmission of KPC-KP.

› Read more

Workshop on migrant health in Oman from 8-10 March 2018

Together with the World Health Organization, the European Centre for Disease Prevention and Control and Oman’s Ministry of Health ESCMID is organizing a postgraduate workshop on migrant health. The course will show how to monitor migrants’ health and how to prevent and control infectious diseases in migrants in Gulf Cooperation Council (GCC) and eastern Mediterranean countries. They will discuss the impact of migrants on the health systems of the hosting countries especially for vaccine preventable diseases, importation of communicable diseases and AMR as well as the role and impact of migrants on the elimination programmes for tuberculosis, malaria, HIV and hepatitis B and C. The grant application deadline for the course is 12 January 2018.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.